Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711)
compared with placebo in the acute treatment of migraine as measured by Pain Freedom
(headache pain intensity level reported as "no pain") at 2 hours post dose using a four point
numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an
optimal dose to support the Phase 3 clinical trials.
Phase:
Phase 2
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc. Bristol-Myers Squibb